Ambeed 大中华区 CN | ZH

中文 - ZH English - EN

Ambeed.cn

搜索

关键字搜索批量搜索

首页 收藏 购物车0
首页 /
抑制剂/激动剂
抗生素和抗病毒
/
抗感染
结构
/
头孢烯类
Antibacterial
/ Cefazolin Sodium Salt/头孢唑啉钠盐

Cefazolin Sodium Salt/头孢唑啉钠盐 {[allProObj[0].p_purity_real_show]}

货号：A188379 同义名： 头孢唑林钠 / Cephazolin sodium; Cefazolin sodium

Cefazolin Sodium Salt是一种β-内酰胺抗生素和第一代头孢菌素，具有杀菌活性。

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Cefazolin Sodium Salt/头孢唑啉钠盐 化学结构 CAS号：27164-46-1
Cefazolin Sodium Salt/头孢唑啉钠盐 化学结构
CAS号：27164-46-1
Cefazolin Sodium Salt/头孢唑啉钠盐 3D分子结构
CAS号：27164-46-1
Cefazolin Sodium Salt/头孢唑啉钠盐 化学结构 CAS号：27164-46-1
Cefazolin Sodium Salt/头孢唑啉钠盐 3D分子结构 CAS号：27164-46-1
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}

{[ getRatePriceInt(item.pr_rmb, 1,1) ]}

{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} 		{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} 现货 1周 咨询 - +
购物车0 收藏 询单

Cefazolin Sodium Salt/头孢唑啉钠盐 纯度/质量文件 产品仅供科研

货号：A188379 标准纯度： {[allProObj[0].p_purity_real_show]}
批次查询： 批次纯度:

全球学术期刊中引用的产品

• Nature, 2025, 645, 793-800. Ambeed. [ A201204 , A444152 , A344107 , A952055 ]
• Cell, 2025. Ambeed. [ A122167 ]
• Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]
• Sig. Transduct. Target. Ther., 2025, 10, 257. Ambeed. [ A104916 ]
• Nat. Nanotechnol., 2025. Ambeed. [ A243018 , A1216705 , A522597 , A125401 , A1355641 ]
更多 >

Cefazolin Sodium Salt/头孢唑啉钠盐 生物活性

描述 Cefazolin sodium is an essential drug that is widely used in clinical therapy for certain infective diseases caused by bacteria[3]. Cefazolin sodium was given intravenously before skin incision (1 g) and at the beginning of CPB (cardiopulmonary bypass) (2 g). CPB may alter the plasma protein binding and possibly distribution of cefazolin[4]. Moreover, cefazolin has a direct anti-inflammatory effect and can attenuate surgery-induced postoperative memory and learning impairment in mice[5]. Cefazolin appears similar to oxacillin for the treatment of complicated MSSA (methicillin-susceptible Staphylococcus aureus) bacteremia but with significantly improved safety[6]. Cefazolin sodium attains high serum levels and is excreted quickly via the urine.

Cefazolin Sodium Salt/头孢唑啉钠盐 细胞实验

Cell Line
Concentration Treated Time Description References
Mouse C8-B4 microglial cells 250 μg/ml 6 or 24 h To determine the anti-inflammatory effect of cefazolin on LPS-induced inflammatory response. Results showed that cefazolin at 250 μg/ml significantly inhibited LPS-induced production of IL-6 and IL-1β. J Neuroinflammation. 2018 Aug 22;15(1):235

Cefazolin Sodium Salt/头孢唑啉钠盐 动物实验

Species
Animal Model
Administration Dosage Frequency Description References
Rats Healthy rats Subcutaneous injection 100 mg/kg Single dose To compare the tissue distribution and plasma elimination kinetics of cefazolin, ceforanide, and cefamandole. Cefazolin had a plasma half-life of 0.5 h, plasma AUC of 184 μg·h/ml, and peak plasma concentration of 140 μg/ml. Measurable concentrations of cefazolin were found in the liver, kidneys, lungs, submaxillary glands, cervical lymph nodes, femur, heart, abdominal muscles, eyes, and testes. The tissue elimination kinetics followed the plasma elimination profiles. Antimicrob Agents Chemother. 1981 Apr;19(4):625-7
Mice SWR/J mouse model Oral 0.125 g/L Short-term 3 days or long-term 14 days To evaluate the impact of cefazolin on the kidney microbiota in mice, results showed that cefazolin led to a loss of uroprotective Lactobacillus spp. and proliferation of Enterobacteriaceae. Nat Commun. 2024 Dec 11;15(1):10509

Cefazolin Sodium Salt/头孢唑啉钠盐 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02216227 Surgical Site Infection Not Applicable Recruiting September 30, 2019 United States, Florida ... 展开 >> Miami VA Healthcare System, Miami, FL Recruiting Miami, Florida, United States, 33125 Contact: Gio J Baracco Lira, MD    305-575-7000 ext 4430    Gio.Baracco@va.gov    Sub-Investigator: Gio J Baracco, MD          United States, Iowa Iowa City VA Health Care System, Iowa City, IA Recruiting Iowa City, Iowa, United States, 52246-2208 Contact: Eli N Perencevich, MD MS BS    319-338-0581 ext 3535    eli.perencevich@va.gov    Principal Investigator: Eli N. Perencevich, MD MS BS          Sub-Investigator: Heather S Reisinger, PhD          Sub-Investigator: Marin L. Schweizer-Looby, PhD BS          Sub-Investigator: Mary S. Vaughan-Sarrazin, PhD MA          United States, Maryland Baltimore VA Medical Center VA Maryland Health Care System, Baltimore, MD Recruiting Baltimore, Maryland, United States, 21201 Contact: Daniel J Morgan, MD MS    (410) 706-1734    Daniel.Morgan2@va.gov    Sub-Investigator: Daniel Josiah Morgan, MD MS          United States, Massachusetts VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA Recruiting Boston, Massachusetts, United States, 02130 Contact: Kalpana Gupta, MD MPH    857-203-5086    kalpana.gupta@va.gov    Sub-Investigator: Kalpana Gupta, MD MPH          United States, Michigan VA Ann Arbor Healthcare System, Ann Arbor, MI Recruiting Ann Arbor, Michigan, United States, 48105 Contact: Suzanne F Bradley, MD    734-845-3072    Suzanne.Bradley2@va.gov    Sub-Investigator: Sarah L. Krein, PhD RN          Sub-Investigator: Suzanne F Bradley, MD          United States, Minnesota Minneapolis VA Health Care System, Minneapolis, MN Recruiting Minneapolis, Minnesota, United States, 55417 Contact: Joseph R Thurn, MD MPH    612-467-4185    seph.thurn@va.gov    Sub-Investigator: Joseph R Thurn, MD MPH          United States, Nebraska Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE Recruiting Omaha, Nebraska, United States, 68105-1873 Contact: Marvin J Bittner, MD    402-995-5219    Marvin.Bittner@va.gov    Sub-Investigator: Marvin J Bittner, MD          United States, Oregon VA Portland Health Care System, Portland, OR Recruiting Portland, Oregon, United States, 97239 Contact: Graeme N Forrest, MBBS MD    503-220-8262 ext 52118    Graeme.forrest@va.gov    Sub-Investigator: Christopher D. Pfeiffer, MD MHS          Sub-Investigator: Graeme N. Forrest, MBBS MD          United States, Texas South Texas Health Care System, San Antonio, TX Recruiting San Antonio, Texas, United States, 78229 Contact: Jose A Cadena Zuluaga, MD    210-617-5300    Jose.Cadena-Zuluaga@va.gov    Sub-Investigator: Luci Leykum, MD MBA MSc          United States, Utah VA Salt Lake City Health Care System, Salt Lake City, UT Recruiting Salt Lake City, Utah, United States, 84148 Contact: Michael A Rubin, MD PhD    (801) 582-1565 ext 1960    michael.rubin2@va.gov    Sub-Investigator: Michael Adam Rubin, MD PhD          United States, Wisconsin William S. Middleton Memorial Veterans Hospital, Madison, WI Recruiting Madison, Wisconsin, United States, 53705 Contact: Christopher J Crnich, MD PhD MS    (608) 256-1901    christopher.crnich@va.gov    Sub-Investigator: Christopher John Crnich, MD PhD MS 收起 <<
NCT02225821 Surgical Wound Infection Phase 4 Completed - Netherlands ... 展开 >> Medisch Centrum Alkmaar Alkmaar, Netherlands Flevoziekenhuis Almere, Netherlands Amstelland Ziekenhuis Amstelveen, Netherlands Academic Medical Center Amsterdam, Netherlands BovenIJ Ziekenhuis Amsterdam, Netherlands Onze Lieve Vrouwe Gasthuis Amsterdam, Netherlands Sint Lucas Andreas Ziekenhuis Amsterdam, Netherlands VU Medisch Centrum Amsterdam, Netherlands Gelre Ziekenhuizen Apeldoorn, Netherlands Rode Kruis Ziekenhuis Beverwijk, Netherlands Amphia Ziekenhuis Breda, Netherlands Reinier de Graaf Delft, Netherlands MC Haaglanden Den Haag, Netherlands Deventer Ziekenhuis Deventer, Netherlands Catharina Ziekenhuis Eindhoven, Netherlands Elkerliek Ziekenhuis Helmond, Netherlands Tergooiziekenhuizen Hilversum, Netherlands Spaarne Ziekenhuis Hoofddorp, Netherlands Westfries Gasthuis Hoorn, Netherlands Rijnland Ziekenhuis Leiderdorp, Netherlands Vlietland Ziekenhuis Schiedam, Netherlands 收起 <<
NCT02344511 Osteomyelitis Phase 3 Withdrawn April 2019 -

Cefazolin Sodium Salt/头孢唑啉钠盐 参考文献

[1]Sivakumar B, Parthasarathy K, et al. Isolation and characterisation of degradation impurities in the cefazolin sodium drug substance. Sci Pharm. 2013 Jun 4;81(4):933-50.

[2]El-Desoky HS, Ghoneim EM, Ghoneim MM. Voltammetric behavior and assay of the antibiotic drug cefazolin sodium in bulk form and pharmaceutical formulation at a mercury electrode. J Pharm Biomed Anal. 2005 Oct 4;39(5):1051-6.

[3]Chen B, Gao ZQ, Liu Y, Zheng YM, Han Y, Zhang JP, Hu CQ. Embryo and Developmental Toxicity of Cefazolin Sodium Impurities in Zebrafish. Front Pharmacol. 2017 Jun 26;8:403.

[4]Asada M, Nagata M, Mizuno T, Uchida T, Kurashima N, Takahashi H, Makita K, Arai H, Echizen H, Yasuhara M. Effects of cardiopulmonary bypass on the disposition of cefazolin in patients undergoing cardiothoracic surgery. Pharmacol Res Perspect. 2018 Nov 5;6(6):e00440.

[5]Liang P, Shan W, Zuo Z. Perioperative use of cefazolin ameliorates postoperative cognitive dysfunction but induces gut inflammation in mice. J Neuroinflammation. 2018 Aug 22;15(1):235.

[6]Li J, Echevarria KL, Hughes DW, Cadena JA, Bowling JE, Lewis JS 2nd. Comparison of cefazolin versus oxacillin for treatment of complicated bacteremia caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2014 Sep;58(9):5117-24.

Cefazolin Sodium Salt/头孢唑啉钠盐 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.10mL

0.42mL

0.21mL

10.49mL

2.10mL

1.05mL

20.99mL

4.20mL

2.10mL

Cefazolin Sodium Salt/头孢唑啉钠盐 技术信息

CAS号27164-46-1
分子式C14H13N8NaO4S3
分子量 476.49
SMILES Code O=C([O-])C(N1[C@@]([H])([C@@H](C1=O)NC(CN2N=NN=C2)=O)SC3)=C3CSC4=NN=C(S4)C.[Na+]
MDL No. MFCD00599428
别名 头孢唑林钠 ;Cephazolin sodium; Cefazolin sodium; SKF 41558; NSC 291561; Cefazolin (sodium salt); Ancef; cefazoline sodium
运输蓝冰
InChI Key FLKYBGKDCCEQQM-WYUVZMMLSA-M
Pubchem ID 23675322
存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Keep in dark place, inert atmosphere, 2-8°C
溶解方案

DMSO: 105 mg/mL(220.36 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

H2O: 100 mg/mL(209.87 mM)

请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶
方案 一
方案 二
配制的工作液建议现用现配，短期内尽快用完。 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶。
方案 一

Tags: Cefazolin | 27164-46-1 | Cephazolin | Anti-infection | Bacterial | Antibiotic | 仅供科研使用 | AmBeed-信号通路专用抑制剂 | Cefazolin Sodium Salt/头孢唑啉钠盐 纯度/质量文件 | Cefazolin Sodium Salt/头孢唑啉钠盐 生物活性 | Cefazolin Sodium Salt/头孢唑啉钠盐 临床数据 | Cefazolin Sodium Salt/头孢唑啉钠盐 参考文献 | Cefazolin Sodium Salt/头孢唑啉钠盐 实验方案 | Cefazolin Sodium Salt/头孢唑啉钠盐 技术信息

AmBeed 相关网站 AmBeed.cn AmBeed.com
AmBeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
    • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    AmBeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质用途提供服务。

    尊敬的 AmBeed 客户您好，
    请您选择所在区域，我们将转接对应客服为您服务！

    热门区域

    A

    B

    C

    F

    G

    H

    J

    L

    N

    Q

    S

    T

    X

    Y

    Z

    热 A B C F G H J L N Q S T X Y Z